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Background: Treatment decisions in advanced non-small cell lung cancer rely on accurate analysis of the EGFR
mutation status in small tissue samples. Sanger sequencing of PCR products is unbiased and cheap, but its detection
threshold requiring 20 % infiltration by malignant cells is not optimal. Commercial kits, based on quantitative real-time
PCR have better detection limits and can detect a wide spectrum of mutations but are considerably more expensive.
Methods: We developed a wild-type blocking PCR for EGFR G719A/S/C (exon 18), exon 19 deletions, and exon 20
insertions using locked nucleic acid (LNA) probes. The amplification products of positive reactions were analyzed
by Sanger sequencing. We retrospectively validated this assay by comparison of the EGFR mutation status as
obtained with Fragment Length Analysis and the Therascreen EGFR RGQ PCR kit.
Results: The EGFR mutation status for exon 18 and 19 as obtained with the LNA-PCR/sequencing assay correlated
adequately with the results obtained by the other independent methods. Due to the lack of structural consistency
among the insertions in exon 20, the latter are less amenable for a LNA-PCR design.
Conclusions: The LNA-PCR/sequencing assay presented here is specific, sensitive, and has a low detection threshold.
In combination with allele-specific PCR reactions for T790M (exon 20) and L858R (exon 21), a wider scope of EGFR
mutations can be assessed at a lower cost.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1272520418142748
Keywords: EGFR mutations, Non-small cell lung cancer, LNA, PCRBackground
Lung cancer is a leading cause of cancer-related mortal-
ity worldwide [1]. Non-small cell lung cancer (NSCLC)
accounts for more than 80 % of all lung cancers. About
ten percent of NSCLC cancers harbor activating muta-
tions in the Epidermal Growth Factor Receptor (EGFR)
gene. The most common activating mutations of EGFR
occur in the intracellular tyrosine kinase domain, i.e. in
exons 18–21 [2, 3]. These mutations lead to constitutive
activation and convey transforming capacity to the
receptor. Deletions in exon 19 and a point mutation
in exon 21 (L858R) account for about 90 % of EGFR* Correspondence: peter.vandenberghe@med.kuleuven.be
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unless otherwise stated.mutations reported to date [4, 5]. The majority (44 to
80 %) of exon 19 deletions are in-frame micro-deletions
encompassing amino acids 746–750 (ELREA) [5, 6].
The G719A mutation within exon 18 results in an amino
acid substitution at position 719, from a glycine (G) to
an alanine (A). Two additional independent mutations
have also been described at this position: G719C
(Cysteine) and G719S (Serine). Collectively, these point
mutations occur with a frequency of approximately 3 %
[5]. G719A/S/C, exon 19 deletions, and L858R muta-
tions are associated with sensitivity to EGFR tyrosine
kinase inhibitors (EGFR-TKIs) gefitinib, erlotinib, or
afatinib [7–10]. Drug resistance emerges most frequently
as a result of a secondary mutation in exon 20 (T790M)
[11, 12]. The T790M mutation is almost always observed
in conjunction with a sensitivity-conferring mutation.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of 3 to 21 base pairs in EGFR exon 20 account for an-
other 4 % of EGFR mutations. These exon 20 insertions
are predominantly clustered between amino acids 767
and 774 and represent a highly heterogeneous family of
activating mutations with a variable length, position,
and amino acid composition. Most patients with tumors
with insertion mutations in exon 20 are less sensitive to
TKIs [13–15].
As the majority of NSCLC cases present with advanced
stage, their diagnosis is usually based on small biopsy and
cytology specimens obtained by bronchoscopic procedures,
and not on surgical resection specimens [16, 17]. Analysis
of the EGFR mutation status on these limited amounts of
tissue sample poses a technical challenge, yet is strictly
required as the results will determine therapeutic decisions.
Several methodologies are available for EGFR mutation
testing [16, 18]. One is direct Sanger sequencing of the
mutated exons. Sanger sequencing is non-biased and
will detect all sequence variants, including rare ones. The
major disadvantage is its detection threshold requiring at
least a 10 % mutant allele fraction, or at least a 20 % ma-
lignant cell fraction. To obviate this, a variety of quantita-
tive real-time PCR (qPCR) methods have been developed.
The group of Dr. Rosell in Spain has developed and
validated a method for EGFR mutation testing in sam-
ples containing less than 150 tumor cells that can be
applied to both fresh and paraffin-embedded biopsies
and cytologic specimens. Their method is based on
micro-dissection of tumor cells directly into PCR buffer,
followed by amplification, and determination of EGFR
status by fragment length analysis of fluorescently-
labeled products (exon 19 deletions) or TaqMan Assay
(exon 20 T790M and exon 21 L858R). Its spectrum is
restricted to mutations in exon 19 and the L858R in
exon 21, which account for the large majority of sensi-
tive EGFR mutations [19].
The Therascreen EGFR RGQ PCR kit (Qiagen) is a
commercial CE-labeled kit for the diagnostic analysis
of EGFR mutation status. The assay is based on allele-
specific amplification, applying the technology of the
Amplification Refractory Mutation System (ARMS)
[20, 21]. The amplification is followed in real-time by
Scorpion technology [22, 23]. The kit allows the detection
of a wider scope of mutations, including 19 deletions of
exon 19, three insertions in exon 20, the point mutations
G719A/S/C (exon 18), S768I, and T790M (exon 20) and
L858R and L861Q (exon 21). In addition to its better
detection threshold, the kit is less time consuming than
Sanger sequencing [18]. The Therascreen assay does how-
ever not yield sequence information about the type of
codon 719 changes, the exon 19 deletions, or the exon 20
insertions. The cost of this assay is also substantially
higher than the cost of Sanger sequencing.The goal of this study was to extend the spectrum of the
Rosell methodology. To this end, we evaluated a LNA
based PCR/sequencing method to detect G719A/S/C mu-
tations, exon 19 deletions and exon 20 insertions. Require-
ments were a detection threshold comparable to that of
commercial kits, and a cost lower than commercial kits.
For convenience, applicability of a single platform was
considered an asset. We developed a wild-type blocking
PCR by addition of a highly sensitive locked nucleic acid
(LNA) probe complementary to the wild-type sequence.
LNA are bicyclic nucleic acids where a ribonucleoside is
linked between the 2’-oxygen and the 4’–carbon atoms
with a methylene unit. For each incorporated LNA mono-
mer, the melting temperature (Tm) of the duplex increases
by 2–8 °C. As a result, LNA probes exhibit unprecedented
thermal stability when hybridized to a complementary
DNA or RNA strand, and substitutions of DNA nucleo-
tides with LNA allow short probes while maintaining a
high Tm. The use of LNA probes complementary to the
wild-type sequence, effectively suppresses amplification of
the wild-type allele and leads to preferential amplification
of the mutant allele [24].
Here, we evaluate the development of a LNA-PCR/
sequencing assay for codon G719 (exon 18), exon 19
deletions, and exon 20 insertions.
Methods
Tumor samples
Our institutional EGFR testing database includes pa-
tients diagnosed at the University Hospitals Leuven with
advanced stage NSCLC, subtyped as adenocarcinoma,
NSCLC-not otherwise specified (NOS) or squamous cell
carcinoma with a negative/light smoking history. For the
LNA study, we included diagnostic tissue specimens ob-
tained by bronchoscopy (bronchial biopsies and endobron-
chial ultrasound guided transbronchial needle aspirations
(EBUS-TBNA)) between September 2010 and December
2012. For the validation study, we used archived surgical
resection specimens from 31 early stage lung adenocarcin-
oma patients.
DNA extraction
For EGFR mutation analysis on small biopsies and
cytology specimens, twelve consecutive 4 μm sections
were prepared from the paraffin block, the first, and
last of which were stained with H&E, and evaluated for
the presence and amount of tumor cells by an experi-
enced pathologist. The proportion of tumor cells was
estimated semi-quantitatively and the representative area
was marked on the H&E slide. After deparaffination
with xylene and alcohol, the tumor foci in the marked
areas were manually macro-dissected, using a mini lam-
botte KA 480/04 (Devroe Instruments, Londerzeel,
Belgium), and collected in microtubes. The tissue was
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was done using the Maxwell16 FFPE tissue LEV DNA
purification kit on the Maxwell16 instrument (Promega,
Madison, WI) according to manufacturer’s instructions.
The concentration of the extracted DNA was measured
using Victor spectrophotometry (Perkin Elmer, Waltham,
MA). For surgical biopsies in the validation study, one
H&E slide followed by 5 serial unstained sections (4 μm
thick) and a final H&E were prepared and both H&E sec-
tions were evaluated. DNA extraction was done using the
QIAamp DNA FFPE Tissue Kit (Qiagen, Valencia, CA)
according to the manufacturer’s instructions. DNA was
quantified by the Quant-iT PicoGreen dsDNA Assay Kit
(Invitrogen by Life Technologies, Grand Island, NY).
LNA-PCR
The LNA suppresses the amplification of the wild-type
allele, leading to preferential amplification of mutant
sequences. The real-time amplification was done on a
LightCycler 480 II system (Roche Applied Science,
Indianapolis, IN). SybrGreen I was used for the detection
of PCR products. Each specimen was subjected to two re-
actions, one without LNA, and one with LNA. Primers
and LNA probe sequences are listed in Table 1. Diag-
nostic samples with known EGFR mutation status as
determined with the Therascreen EGFR RGQ PCR kit
were used as test material. Fifty ng of input DNA was
used. Each qPCR reaction was performed in a sealed
LightCycler 480 Multiwell Plate 96 (Roche) in a 25 μl
volume mixture containing 50 ng of genomic DNA,
6.25 μl LightCycler 480 SYBR Green I Master (Roche),
6.25 μl TaqMan Universal PCR Master Mix (Applied
Biosystems by Life Technologies, Grand Island, NY),
and 0.12 μM forward and reverse primer (= control reac-
tion). In the LNA reaction, 0.6 μM of the LNA probe was
added to the PCR mixture. The PCR amplification was car-
ried out as follows: 10 minutes at 95 °C and 45 cycles ofTable 1 Primers and LNA probes for LNA assay with Sanger sequen
Exon Name Target Amp
18 18 FP G719A/S/C 112
18 RP
18 LNA
19 19 FP Deletions 176
19 RP
19 LNA
20 20 FP Insertions 161
20 RP
20 LNA
- M13-tag 1 For Sanger sequencing -
- M13-tag 2 For Sanger sequencing -
Italic: M13-sequencing tag; F: forward primer; R: reverse primer; LNA: locked nucleic30 sec. at 95 °C and 45 sec. at 62 °C. LightCycler 480 soft-
ware release 1.5.0 was used for mutation identification by
Advanced Relative Quantification Analysis. Sample delta
crossing point (ΔCp)-values were calculated as the differ-
ence between the Cp-value of the LNA reaction and the
Cp of the control reaction. Reactions with a ΔCp less than
the cut-off value were considered positive, i.e. potentially
indicating an EGFR mutant, and the LNA-PCR products
of these cases were subjected to Sanger sequencing for
confirmation.
In a theoretical situation with 100 % mutant tumor,
the ΔCp is expected to be zero. At 10 % mutant, the ex-
pected ΔCp-value is 3.32 (2log10 = 3.32). At 1 % mutant,
the expected ΔCp will be 6.64 (2log100 = 6.64). Based on
this theoretical assumption, we performed Sanger se-
quencing on cases with a ΔCp less than 6.6.
Sanger sequencing
Use of PCR primers containing M13-tags allows geno-
typing of mutations directly by sequencing without a
need for additional PCR reactions. The PCR product
was purified by ExoSAP-IT treatment (Affymetrix, Santa
Clara, CA). Sanger sequencing of LNA-PCR products
was performed using M13–sequencing primer tag 2 for
exon 18, M13–sequencing primer tag 1 for exon 19
(Table 1) and the BigDye Terminator v3.1 Cycle Sequen-
cing Kit (Applied Biosystems) on a ABI Prism 3100 Gen-
etic Analyzer (Applied Biosystems). Sequencing was
done in one direction only because of binding of the
LNA probe to either the 5’ or 3’ end of the wild-type
amplicon. Results were compared with the EGFR wild-
type sequence [GenBank:NM_005228].
EGFR mutation testing with Therascreen EGFR RGQ
PCR kit
Mutation analysis of EGFR using the Therascreen EGFR
RGQ PCR kit (Qiagen, Valencia, CA) was performed oncing confirmation












acid; bp: base pairs
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Indianapolis, IN). qPCR reactions were carried out in a
total volume of 25 μl (19.5 μl reaction mix + 0.5 μl Taq
DNA polymerase + 5 μl sample) and the following cycle
conditions: 95 °C for 15 min, 45 cycles at 95 °C for 30 sec
and 60 °C for 1 min. 50 ng of genomic DNA was used.
Fragment Length Analysis
For PCR amplification of EGFR exon 19, the following
primers were used: forward 5’–ACTCTGGATCCCAG
AAGGTGAG–3’ and reverse 5’–FAM-CCACACAGC
AAAGCAGAAACTC–3’. PCR was performed in 25 μl
volumes adding 5 ng of DNA, 2.5 μl GeneAmp Gold
Buffer, 200 μM dNTPs, 1.5 mM MgCl2, 0.625 U Ampli-
TaqGold DNA Polymerase (Applied Biosystems by Life
Technologies, Grand Island, NY), and 0.5 μM of each
primer. Amplification was done for 32 cycles (30 seconds
at 95 °C, 30 seconds at 61 °C, and 1 minute at 72 °C).
0.2 μl of PCR-product was mixed with 0.5 μl of Rox size
standard (Applied Biosystems) and denatured in 20 μl
HiDi formamide (Applied Biosystems) at 95 °C for
3 minutes. Separation was done with a four-color laser-
induced fluorescence capillary electrophoresis system
(ABI Prism 3100 Genetic Analyzer, Applied Biosystems).
The collected data were evaluated with the ABI Prism
GeneScan and Genotyper software.
Results
We developed an assay for EGFR mutations G719A/S/C
in exon 18 and deletions in exon 19 based on a LNA
wild-type blocking PCR followed by Sanger sequencing
of the amplicon.
Diagnostic samples with known EGFR status (wild-
type or mutant) were used as test materials. The samples
are listed in Table 2 with their ΔCp and EGFR status.
The ΔCp of wild-type samples was comparable with the
ΔCp of the CCL221 cell line, used as negative control
and far above the cut-off value of 6.6. We had two cases
with G719 mutations (exon 18). They had a ΔCp-value
of 2.3 and 1.4. Subsequent Sanger sequencing of the LNA-
PCR product indicated a p.G719C mutation for sample
L62 and a p.G719A mutation for sample L77. We ana-
lyzed five cases with exon 19 deletions. The ΔCp for these
samples was between 1.4 and 5.6. The exon 19 deletion
was confirmed by Sanger sequencing in all five samples.
All mutated samples had a deletion of fifteen nucleotides,
corresponding with the ELREA amino acid string.
We performed dilution experiments to evaluate the
detection threshold of the LNA-PCR/sequencing assay.
A histological specimen consisting of approximately
100 % nucleated tumor cells and harboring a known
exon 19 deletion was selected. The tumor-derived DNA
was mixed with DNA from EGFR wild-type patients in ra-
tios ranging from high to low tumor content (100 %–0 %tumor, serially diluted one in two times). Reactions were
performed as described previously and carried out in du-
plicate. The theoretically chosen ΔCp cut-off value of 6.6
corresponded with an estimated malignant cell fraction of
3.125 %, while a tumor cell content of 1.5625 % yielded
6.75 as ΔCp (Table 3).
We also attempted to design a LNA-PCR assay for the
insertions in exon 20. However, the ΔCp was between
6.6 and 6.8 for wild-type samples and between 4.2 and
10.0 for the three mutant samples tested. To resolve this
discrepancy, we subjected the latter mutant samples to
direct Sanger sequencing. This revealed the following
mutation types: p.V769_D770insASV (duplication, ΔCp:
4.2), D770_N771insGL (random nucleotide insertion,
ΔCp: 6.1), and p.H773_V774insNPH (duplication, ΔCp:
10.0). The LNA used for exon 20 insertions binds to nu-
cleotides c.2301 to c.2311 (i.e. the last nucleotide of
codon 767 to the first nucleotide of codon 771 inclu-
sive). Thus binding of this LNA is not affected by the
p.H773_V774insNPH, explaining the high ΔCp in this
case. In the two other cases, there is a mismatch of one
nucleotide between the targeted mutant sequence and
the LNA sequence which is predicted to interfere with
LNA binding, thus explaining the lower delta CP.
In conclusion the G719A/S/C in exon 18 and deletions
in exon 19 were eligible for a LNA-PCR/sequencing
assay. Due to technical reasons related to exon 20 inser-
tions, a LNA-PCR testing method for this type of muta-
tions is less straightforward.
Validation study
We analyzed the mutation status of 31 resection speci-
mens with the following methods: LNA-PCR with
Sanger sequencing confirmation, Fragment Length Ana-
lysis, and the Therascreen EGFR RGQ PCR kit. First, the
EGFR status of the resection specimens was determined
by the LNA-PCR/sequencing testing method comprising
exon 18 and 19. In this series of 31 specimens, no cases
with G719A/S/C mutations were identified. The Ad-
vanced Relative Quantification Analysis of the LightCycler
480 software release 1.5.0 yielded ΔCp-values between 6.1
and 8.4 for the G719A/S/C LNA-PCR (Table 4). Sample
ID29 was considered as a failure because the control Cp-
value was 40. Sample ID10 had a ΔCp of 3.2. However, se-
quencing of the product of the LNA reaction of sample
ID10 revealed gga for codon 719, a silent mutation trans-
lated to glycine (G). Due to the design of the LNA probe
to block ggc, amplification of the gga allele was not
blocked. Sample ID30 had a ΔCp of only 5.4, but the con-
trol Cp-value of 34.7 indicated limited amounts of good
quality DNA. Because the validation cohort did not harbor
any G719 mutations, we included an additional case with
a positive G719 mutation, identified by a Therascreen test-
ing of an EBUS specimen. The ΔCp-value of 2.1 indicated
Table 2 Comparison between LNA assay and Sanger sequencing
Sample % tumor ΔCp G719A/S/C LNA G719A/S/C Sanger sequencing
CCL221 10.4 negative n.d
L86 65 10.6 negative n.d
L18 30 10.4 negative n.d
L30 15 10.4 negative n.d
L62 20 2.3 positive ? p.G719C (c.2155G > T)
L77 50 1.4 positive ? p.G719A (c.2156G > C)
Sample % tumor ΔCp deletions 19 LNA deletions 19 Sanger sequencing
CCL221 10.8 negative n.d
L86 65 10.4 negative wild-type
L18 30 10.1 negative n.d
L95 10 5.6 positive ? p.E746_A750del (c.2235_2249del15)
L91 100 1.4 positive ? p.E746_A750del (c.2236_2250del15)
L93 50 3.6 positive ? p.E746_A750del (c.2235_2249del15)
L58 10 2.9 positive ? p.E746_A750del (c.2235_2249del15)
L55 70 1.8 positive ? p.E746_A750del (c.2235_2249del15)
Cp: crossing point; LNA: locked nucleic acid; n.d: not done
Vliegen et al. Diagnostic Pathology  (2015) 10:57 Page 5 of 8a positive reaction. Sanger sequencing of the LNA-PCR
product confirmed a p.G719C mutation (c.2155G >T).
This case, together with the silent mutation provide proof-
of-principle that the wild-type blocking PCR detects codon
719 mutations, but more samples are required to deter-
mine sensitivity and specificity of the test for codon 719.
An exon 19 deletion mutation was found in six of the 31
resection specimens, with ΔCp-values ranging between 0.3
and 1.8. Sanger sequencing of the LNA products confirmed
these deletions (Table 4). The ΔCp-values for the samples
with a wild-type status varied between 6.1 to 9.2 with three
exceptions. Sample ID20 had a ΔCp of 5.2 but had a higher
Cp value of the control reaction (34.8). Samples ID25 and
ID30 had also a higher control Cp value (35.2 and 39.0). Se-
quencing data of these three samples confirmed the ab-
sence of mutations. Again the control Cp-value of sample
ID29 was above 40 and considered as technical failure due
to poor DNA quality.Table 3 Dilution experiment LNA assay for EGFR exon 19
deletions
Sample Cp controle Cp LNA ΔCp
100 % mutant 29.66 30.93 1.27
50 % mutant 29.89 31.91 2.02
25 % mutant 30.13 33.37 3.24
12.5 % mutant 30.12 33.92 3.80
6.25 % mutant 30.35 35.78 5.43
3.125 % mutant 30.56 36.34 5.78
1.5625 % mutant 30.21 36.96 6.75
100 % wild-type 29.93 39.70 9.77
Cp: crossing point; LNA: locked nucleic acidIn the second step of the validation study the 31 resec-
tion specimens were subjected to Fragment Length Ana-
lysis (exon 19) and to the Therascreen EGFR RGQ PCR
kit (exon 18 and 19). The results were summarized in
Table 4. Sample ID29 and ID30 were excluded due to
poor DNA quality as seen before in the LNA-PCR/
sequencing testing method.
The EGFR mutation status obtained with our LNA-
PCR/sequencing assay therefore correlated adequately
with the results obtained by the other methods.
Discussion
Activating mutations of EGFR observed in NSCLC occur
in the intracellular tyrosine kinase domain, i.e. within
exons 18–21 of the receptor [2, 3]. The most common
EGFR mutations are small in-frame deletions in exon 19
and the L858R point mutation in exon 21 [4, 5]. They
account for about 90 % of all EGFR mutations reported
in lung adenocarcinoma and are known to be sensitive
to the EGFR-TKIs gefitinib, erlotinib, or afatinib [7–10].
A high response rate to these TKIs was also seen in pa-
tients with a somatic mutation in exon 18 (G719A/S/C),
which occurs with a frequency of approximately 3 %
[5, 7–9]. By contrast, the T790M mutation in exon 20 is
associated with acquired resistance to TKIs [11, 12] and
the insertions in exon 20 are less sensitive to EGFR-TKIs
compared with other sensitizing mutations [13, 14].
Treatment decisions in advanced stage rely on accur-
ate analysis of the EGFR mutation status in small tissue
samples obtained by bronchoscopic procedures [16, 17].
However, mutation analysis on small FFPE tissue sam-
ples faces several challenges. Some are sample related,











ID1 6.1 neg. / n.d 7.7 neg. / n.d wild-type wild-type
ID2 6.8 neg. / n.d 1.3 pos. ? / n.d exon 19 deletion exon 19 deletion (15 bp)
ID3 7.3 neg. / n.d 7.2 neg. / n.d wild-type wild-type
ID4 6.7 neg. / n.d 8.4 neg. / n.d wild-type wild-type
ID5 7.2 neg. / n.d 8.0 neg. / n.d wild-type wild-type
ID6 7.2 neg. / n.d 6.5 neg. / n.d wild-type wild-type
ID7 7.1 neg. / n.d 7.5 neg. / n.d wild-type wild-type
ID8 7.4 neg. / n.d 7.3 neg. / n.d wild-type wild-type
ID9 7.1 neg. / n.d 8.6 neg. / n.d wild-type wild-type
ID10 3.2 pos. ? / wild-type 6.6 neg. / wild-type wild-type wild-type
ID11 7.1 neg. / n.d 7.0 neg. / wild-type wild-type wild-type
ID12 7.1 neg. / n.d 7.3 neg. / n.d wild-type wild-type
ID13 7.5 neg. / n.d 1.7 pos. ? / p.E746_A750del c.2235_2249del15 exon 19 deletion exon 19 deletion (15 bp)
ID14 6.6 neg. / wild-type 9.2 neg. / n.d wild-type wild-type
ID15 7.0 neg. / n.d 7.2 neg. / n.d wild-type wild-type
ID16 7.3 neg. / n.d 0.3 pos. ? / n.d exon 19 deletion exon 19 deletion (18 bp)
ID17 7.5 neg. / n.d 7.2 neg. / n.d wild-type wild-type
ID18 6.8 neg. / n.d 8.5 neg. / n.d wild-type wild-type
ID19 6.8 neg. / n.d 1.8 pos. ? / p.E746_A750del c.2235_2249del15 exon 19 deletion exon 19 deletion (15 bp)
ID20 6.8 neg. / n.d 5.2 pos. ? / wild-type wild-type wild-type
ID21 6.9 neg. / n.d 0.4 pos. ? / p.L747_P753 > S c.2240_2257del18 exon 19 deletion exon 19 deletion (18 bp)
ID22 7.3 neg. / n.d 6.1 neg. / wild-type wild-type wild-type
ID23 7.5 neg. / n.d 8.2 neg. / n.d wild-type wild-type
ID24 7.3 neg. / n.d 8.9 neg. / n.d wild-type wild-type
ID25 6.9 neg. / n.d 4.9 pos. ? / wild-type wild-type wild-type
ID26 6.9 neg. / n.d 7.0 neg. / n.d wild-type wild-type
ID27 8.4 neg. / n.d 2.7 pos. ? / p.E746_A750del c.2235_2249del15 exon 19 deletion exon 19 deletion (15 bp)
ID28 7.5 neg. / n.d 7.5 neg. / n.d wild-type wild-type
ID29 / / / / / wild-type
ID30 5.4 pos. ? / wild-type 1.0 pos. ? / wild-type / wild-type
ID31 7.7 neg. / n.d 8.9 neg. / n.d wild-type wild-type
*:G719X reaction mix and deletions 19 reaction mix; Cp: crossing point; LNA: locked nucleic acid; del: deletion; bp: base pairs; neg.: negative result; n.d: not done; pos.: positive result
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tumor cell content, and suboptimal DNA quality. Other
concerns are related to the performance characteristics
of the technology used for mutation analysis, e.g. the detection
threshold, the mutation spectrum, the cost of the consumables
and the hands-on time [25].
We present a wild-type blocking LNA-PCR amplifica-
tion assay followed by confirmation by sequencing of
amplification product of positive reactions. The assay
determines the EGFR mutation status of codon G719
(exon 18) and exon 19 deletions and can be an alterna-
tive for commercially available kits, as codon G719mutations were not in the scope of previously published
non-commercial methodologies [19]. We have validated
results for exon 18 and for exon 19. Based on a theoret-
ical assumption, the ΔCp cut-off value was initially set
at 6.6: specimens with a lower ΔCp were considered as
potentially indicative of a mutation and the amplification
product was submitted to Sanger sequencing for con-
firmation. This theoretical ΔCp threshold chosen corre-
sponded with a threshold of 3.125 % infiltration by
malignant cells under experimental conditions. This dif-
ference with the theoretical calculation is likely due to
PCR efficiency less than 100 %. However this detection
Vliegen et al. Diagnostic Pathology  (2015) 10:57 Page 7 of 8threshold is better than conventional Sanger sequencing,
competitive with the Therascreen assay, and therefore
adequate for clinical testing.
Exon 20 insertions and duplications are less suited for
wild-type blocking approaches. This is due to the mo-
lecular heterogeneity of exon 20 EGFR mutations (Cata-
logue of Somatic Mutations, http://cancer.sanger.ac.uk/
cosmic), as we have also shown in our series. This
known heterogeneity of insertions/duplications would
require the design of several LNA probes, defeating the
purpose of a simple wild-type blocking strategy to screen
for exon 20 insertions. To our knowledge, there are no
published reports on LNA technology for exon 20 inser-
tions. Other techniques such as fragment length analysis
are more appropriate, if one wishes to test for this class
of EGFR mutations.
We also found a ΔCp less than 6.6 in three specimens
with low amounts/quality of extracted DNA, which were
not confirmed by Sanger sequencing. Larger validation
series should be investigated in order to define the opti-
mal ΔCp as well as control Cp value cut-offs, which
compromise best between sensitivity and specificity. For
the time being, we consider it safest not to reject sam-
ples with high control Cp values, as the final results de-
pend on confirmation by sequencing of the generated
amplicon product anyway.
The combination of allele-specific PCR reactions for
the T790M (exon 20) and L858R (exon 21) point muta-
tions with this assay, has a wider scope of EGFR muta-
tions. Introduction of minor modifications of Rosell’s
TaqMan assay for T790M and L858R, allows to adapt
the latter assays to the LightCycler 480 II instrument.
Cost calculation indicated that the reagent cost for these
tests on a LightCycler platform is only about 25 % com-
pared with the Therascreen EGFR RGQ PCR kit (based
on list prices). However, these assays require slightly
more hands-on time, due to the need for confirmation
of positive cases, which results in a higher personnel
cost. Overall, the cost remains 25 to 50 % lower in com-
parison with the Therascreen testing method.Conclusions
In conclusion, we propose an alternative methodology,
to determine the EGFR mutation status for G719 (exon
18) and exon 19 deletions in NSCLC patients in clinical
routine. The LNA-PCR/sequencing assay needs less
input DNA, is specific, sensitive, and has a detection
threshold of 3.125 % malignant cells. In combination
with allele-specific PCR reactions for T790M (exon 20)
and L858R (exon 21), this methodology allows to assess
a wider scope of clinically relevant mutations, provides
sequence information, and runs at a lower cost than
available commercial kits.Abbreviations
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